Idioma:

Ticagrelor Enhances Adenosine-Induced Coronary Vasodilatory Responses in Humans

Wittfeldt, Ann, MD ; Emanuelsson, Håkan, MD, PhD ; Brandrup-Wognsen, Gunnar, MD, PhD ; van Giezen, J.J.J., PhD ; Jonasson, Jenny, PhD ; Nylander, Sven, PhD ; Gan, Li-Ming, MD, PhD

Journal of the American College of Cardiology, 2013-02, Vol.61 (7), p.723-727 [Periódico revisado por pares]

New York, NY: Elsevier Inc

Texto completo disponível

Citações Citado por

Enviar para

Título:
Ticagrelor Enhances Adenosine-Induced Coronary Vasodilatory Responses in Humans
Autor: Wittfeldt, Ann, MD ; Emanuelsson, Håkan, MD, PhD ; Brandrup-Wognsen, Gunnar, MD, PhD ; van Giezen, J.J.J., PhD ; Jonasson, Jenny, PhD ; Nylander, Sven, PhD ; Gan, Li-Ming, MD, PhD
Assuntos: Acute coronary syndromes ; acute myocardial-infarction ; adenosine ; Adenosine - analogs & derivatives ; Adenosine - pharmacology ; adjunct ; Adolescent ; Adult ; Biological and medical sciences ; Blood Flow Velocity - drug effects ; Blood Flow Velocity - physiology ; Cardiac and Cardiovascular Systems ; Cardiology ; Cardiology. Vascular system ; Cardiovascular ; clopidogrel ; Confidence intervals ; coronary blood flow ; Coronary heart disease ; Coronary Vessels - drug effects ; Coronary Vessels - physiology ; Cross-Over Studies ; Double-Blind Method ; Drug Synergism ; Drug therapy ; dyspnea ; Flow velocity ; Heart ; Heart attacks ; Humans ; Internal Medicine ; Kardiologi ; Male ; Medical sciences ; multicenter ; Physiology ; Purinergic P2Y Receptor Antagonists - pharmacology ; ticagrelor ; trial ; Up-Regulation - drug effects ; Up-Regulation - physiology ; Variance analysis ; Vasodilation - drug effects ; Vasodilation - physiology ; Young Adult
É parte de: Journal of the American College of Cardiology, 2013-02, Vol.61 (7), p.723-727
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-News-1
ObjectType-Feature-3
content type line 23
Descrição: Objectives This study was undertaken to determine if ticagrelor augments adenosine-induced coronary blood flow and the sensation of dyspnea in human subjects. Background Ticagrelor is a P2Y12 receptor antagonist that showed superior clinical benefit versus clopidogrel in a phase III trial (PLATO [Platelet Inhibition and Patient Outcomes]). Ticagrelor has been shown to inhibit cell uptake of adenosine and enhance adenosine-mediated hyperemia responses in a dog model. Methods In this double-blind, placebo-controlled study, 40 healthy male subjects were randomized to receive a single dose of ticagrelor (180 mg) or placebo in a crossover fashion. Coronary blood flow velocity (CBFV) was measured by using transthoracic Doppler echocardiography at rest after multiple stepwise adenosine infusions given before and after study drug, and again after the infusion of theophylline. Results Ticagrelor significantly increased the area under the curve of CBFV versus the adenosine dose compared with placebo (p = 0.008). There was a significant correlation between ticagrelor plasma concentrations and increases in the area under the curve (p < 0.001). In both treatment groups, the adenosine-induced increase in CBFV was significantly attenuated by theophylline, with no significant differences between subjects receiving ticagrelor or placebo (p = 0.39). Furthermore, ticagrelor significantly enhanced the sensation of dyspnea during adenosine infusion, and the effects were diminished by theophylline. Conclusions Ticagrelor enhanced adenosine-induced CBFV and the sensation of dyspnea in these healthy male subjects via an adenosine-mediated mechanism. (Study to Assess the Effect of Ticagrelor on Coronary Blood Flow in Healthy Male Subjects; NCT01226602 )
Editor: New York, NY: Elsevier Inc
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Ticagrelor Enhances Adenosine-Induced Coronary Vasodilatory Responses in Humans

Wittfeldt, Ann, MD ; Emanuelsson, Håkan, MD, PhD ; Brandrup-Wognsen, Gunnar, MD, PhD ; van Giezen, J.J.J., PhD ; Jonasson, Jenny, PhD ; Nylander, Sven, PhD ; Gan, Li-Ming, MD, PhD

New York, NY: Elsevier Inc

Buscando em bases de dados remotas. Favor aguardar.